Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Acetaminophen Prescribed to Over 3 Million Patients in July due Possibly to COVID-19 Vaccine Reactions: Survey
September 1, 2021
- Sawai’s Rising Shipment Controls Now Hit 420 Products
September 1, 2021
- Lilly, Daiichi Sankyo Tie Up on Another Migraine Drug in Japan
August 31, 2021
- Lixiana Hits Goal in High-Risk AF Patients after Heart Valve Procedure
August 31, 2021
- Alnylam’s 2nd siRNA Therapy Givlaari Hits Japan Market
August 31, 2021
- Santen Files Diquas Follow-Up for Dry Eye in Japan
August 31, 2021
- Otsuka Launches Migraine Drug Ajovy in Japan
August 31, 2021
- Tagrisso Filed in Japan for Adjuvant Therapy in EGFR NSCLC
August 31, 2021
- Active Investments in Biotech Upstarts Needed to Create Healthcare Ecosystems: Shonan iPark Manager
August 30, 2021
- Medical Societies Issue Joint Statement in Face of Possible Stockout of Abraxane, Calling for Continued Treatment
August 30, 2021
- Nippon Shinyaku Aims to Maximize Value of Viltepso, Double Sales, Operating Profits in 10 Years: President
August 27, 2021
- Chugai to File Antibody Cocktail for COVID-19 Prevention among Close Contact Individuals
August 27, 2021
- Wakamoto Kicks Off MaQaid PIII Study in China, Eyes Launch in FY2023
August 27, 2021
- Rakuten Medical Eyes Label Expansion for Photoimmunotherapy, Asia as Key Market
August 26, 2021
- ASKA to Accelerate Innovative Pharma Biz, Not Generics; President Sees Trivial Impact from Follow-On Blopress AG
August 25, 2021
- All Ranitidine Products to Be Discontinued in Japan as Nipro to End Injection Sales
August 25, 2021
- Nipro to Develop AI System to Predict Severe COVID-19
August 25, 2021
- Meiji’s PDE4 Inhibitor Delivers in PI; PII Psoriasis Trial Slated to Begin Next Year
August 25, 2021
- All 60 Subjects Given 1st Dose of Shionogi COVID-19 Jabs in Japan PI/PII
August 25, 2021
- Drug Makers’ Q1 Operating Profits Eclipsing Projections on One-Time Gains, Product Growth
August 24, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…